Trial Profile
A prospective study to evaluate efficacy of rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 23 Nov 2015 New trial record